Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors

[1]  M. Syed,et al.  A robotic pill for oral delivery of biotherapeutics: safety, tolerability, and performance in healthy subjects , 2021, Drug delivery and translational research.

[2]  Ali Khademhosseini,et al.  Micro and nanoscale technologies in oral drug delivery , 2020, Advanced Drug Delivery Reviews.

[3]  S. Mitragotri,et al.  Ionic Liquids and Deep Eutectic Solvents for Enhanced Delivery of Antibodies in the Gastrointestinal Tract , 2020, Advanced Functional Materials.

[4]  D. Drucker.  Advances in oral peptide therapeutics , 2019, Nature Reviews Drug Discovery.

[5]  Adrian Berger,et al.  Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability , 2019, Nature Biomedical Engineering.

[6]  Robert Langer,et al.  A luminal unfolding microneedle injector for oral delivery of macromolecules , 2019, Nature Medicine.

[7]  A. Dhalla,et al.  Jejunal wall delivery of insulin via an ingestible capsule in anesthetized swine—A pharmacokinetic and pharmacodynamic study , 2019, Pharmacology research & perspectives.

[8]  Giovanni Traverso,et al.  Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide. , 2019, Journal of pharmaceutical sciences.

[9]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[10]  R. Pratley,et al.  Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial , 2019, The Lancet.

[11]  A. Bernkop‐Schnürch,et al.  Hydrophobic ion-pairs and lipid-based nanocarrier systems: The perfect match for delivery of BCS class 3 drugs. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[12]  T. Heise,et al.  Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. , 2019, The lancet. Diabetes & endocrinology.

[13]  Robert Langer,et al.  An ingestible self-orienting system for oral delivery of macromolecules , 2019, Science.

[14]  Yatin R. Gokarn,et al.  Non-invasive delivery strategies for biologics , 2018, Nature Reviews Drug Discovery.

[15]  A. Bernkop‐Schnürch,et al.  SEDDS: A game changing approach for the oral administration of hydrophilic macromolecular drugs. , 2019, Advanced drug delivery reviews.

[16]  J. Ahnfelt-Rønne,et al.  Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist , 2018, Science Translational Medicine.

[17]  Samir Mitragotri,et al.  Ionic liquids for oral insulin delivery , 2018, Proceedings of the National Academy of Sciences.

[18]  S. Mitragotri,et al.  Intestinal micropatches for oral insulin delivery , 2017, Journal of drug targeting.

[19]  David J Brayden,et al.  Oral delivery of peptides: opportunities and issues for translation. , 2016, Advanced drug delivery reviews.

[20]  Yuhong Cao,et al.  Fabrication of Sealed Nanostraw Microdevices for Oral Drug Delivery. , 2016, ACS nano.

[21]  Pilar Ventosa-Andrés,et al.  DRUG SOLUBILITY : IMPORTANCE AND ENHANCEMENT TECHNIQUES , 2016 .

[22]  Robert Langer,et al.  Microneedles for drug delivery via the gastrointestinal tract. , 2015, Journal of pharmaceutical sciences.

[23]  B. Glaser,et al.  Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. , 2015, The Journal of clinical endocrinology and metabolism.

[24]  A. Griffiths,et al.  Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. , 2014, Journal of Crohn's & colitis.

[25]  R. Fanelli,et al.  Adverse events of upper GI endoscopy. , 2012, Gastrointestinal endoscopy.

[26]  Kimberly N. Walter,et al.  Utilities and disutilities for attributes of injectable treatments for type 2 diabetes , 2011, The European Journal of Health Economics.

[27]  R. Cuddihy,et al.  Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial , 2010, The Lancet.

[28]  S. Gough,et al.  Delayed initiation of subcutaneous insulin therapy after failure of oral glucose‐lowering agents in patients with Type 2 diabetes: a population‐based analysis in the UK , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[29]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[30]  R. Boulton,et al.  Management of swallowed razor blades—retrieve or wait and see? , 2004, Gut.

[31]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[32]  Donald E. Chickering,et al.  Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.

[33]  J. Losanoff,et al.  Ingested Foreign Bodies of the Gastrointestinal Tract: Retrospective Analysis of 542 Cases , 1996, World Journal of Surgery.

[34]  W. A. Webb.  Management of foreign bodies of the upper gastrointestinal tract: update. , 1995, Gastrointestinal endoscopy.

[35]  G. Ginsberg.  Management of ingested foreign objects and food bolus impactions. , 1995, Gastrointestinal endoscopy.

[36]  L. Bolondi,et al.  Measurement of gastric emptying time by real-time ultrasonography. , 1985, Gastroenterology.